Alembic Pharmaceuticals Schedules Investor Meetings with Major Institutional Investors

1 min read     Updated on 04 Mar 2026, 07:51 PM
scanx
Reviewed by
Jubin VScanX News Team
Overview

Alembic Pharmaceuticals Limited has scheduled one-on-one investor meetings with five major institutional investors including HDFC Mutual Fund, TATA AIA Life Insurance, HDFC Life Insurance, Birla Life Insurance, and ICICI Prudential Mutual Fund on March 6, 2026 in Mumbai. The company has properly notified stock exchanges about these meetings under Regulation 30 compliance requirements.

34179665

*this image is generated using AI for illustrative purposes only.

Alembic Pharmaceuticals Limited has announced scheduled one-on-one investor meetings with major institutional investors, demonstrating the company's commitment to maintaining strong investor relations and transparency.

Meeting Details

The pharmaceutical company's management will conduct individual meetings with several prominent institutional investors on March 6, 2026 in Mumbai. These meetings represent an important aspect of the company's investor engagement strategy.

Parameter: Details
Meeting Date: March 6, 2026
Location: Mumbai
Meeting Type: One-on-one investor meetings
Notification Date: March 4, 2026

Participating Institutional Investors

The meetings will include representatives from five major institutional investors, reflecting significant interest from the investment community:

  • HDFC Mutual Fund
  • TATA AIA Life Insurance
  • HDFC Life Insurance
  • Birla Life Insurance
  • ICICI Prudential Mutual Fund

Regulatory Compliance

The company has formally notified both BSE Limited and National Stock Exchange of India Limited about these investor meetings as part of its disclosure obligations under Regulation 30. Company Secretary Manisha Saraf signed the notification on March 4, 2026, ensuring proper compliance with regulatory requirements.

Investor Engagement Significance

These one-on-one meetings provide an opportunity for institutional investors to engage directly with the company's management team. Such interactions typically allow for detailed discussions about business performance, strategic initiatives, and future prospects, facilitating better understanding between the company and its institutional stakeholders.

Historical Stock Returns for Alembic Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
-0.99%-9.24%-10.71%-26.02%-6.21%-25.34%
Alembic Pharmaceuticals
View Company Insights
View All News
like15
dislike

Alembic Pharmaceuticals Issues Postal Ballot Notice for Director Appointment and Professional Fee Approval

3 min read     Updated on 27 Feb 2026, 06:20 PM
scanx
Reviewed by
Suketu GScanX News Team
Overview

Alembic Pharmaceuticals Limited has issued a postal ballot notice dated 27th February, 2026, for two key resolutions. The company seeks shareholder approval for appointing Mr. Rajkumar Baheti as Non-Executive Non-Independent Director effective 1st April, 2026, and approving professional fees up to Rs. 2,50,00,000 per annum. The e-voting period runs from 2nd March to 31st March, 2026, with results expected by 2nd April, 2026.

33742204

*this image is generated using AI for illustrative purposes only.

Alembic Pharmaceuticals Limited has issued a postal ballot notice dated 27th February, 2026, seeking shareholder approval for two significant corporate governance matters through remote e-voting.

Key Resolutions for Shareholder Approval

The pharmaceutical company has proposed two resolutions for member consideration. The first involves the appointment of Mr. Rajkumar Baheti (DIN: 00332079) as Non-Executive Non-Independent Director, while the second seeks approval for professional fee payments to the same individual.

Resolution Details: Particulars
Resolution 1: Appointment of Mr. Rajkumar Baheti as Non-Executive Non-Independent Director
Resolution Type: Ordinary Resolution
Effective Date: 1st April, 2026
Resolution 2: Approval of Professional Fees
Resolution Type: Special Resolution
Maximum Annual Fees: Rs. 2,50,00,000

Leadership Transition Details

Mr. Rajkumar Baheti will complete his tenure as Executive Director on 31st March, 2026. The Board of Directors, based on the Nomination and Remuneration Committee's recommendation, approved his transition to Non-Executive Non-Independent Director role effective 1st April, 2026. This transition aims to ensure continuity at the Board level during the management succession process.

The proposed director brings over 45 years of professional experience in finance, taxation, regulatory compliance, and corporate governance. He is a fellow member of both the Institute of Chartered Accountants of India and the Institute of Company Secretaries of India, having been associated with the company as a Director since its incorporation.

Professional Services Engagement

The second resolution addresses the approval of professional fees for Mr. Baheti's consultancy services in his individual capacity. The professional engagement covers strategic inputs to the Board and senior management, advisory support for legacy matters, and transitional support during management succession.

Fee Structure: Details
Professional Fees: Up to Rs. 2,50,00,000 per annum
Additional Components: Applicable taxes and out-of-pocket expenses
Engagement Period: 1 year from 1st April, 2026
Sitting Fees: As approved by Board for meeting attendance
Turnover Percentage: 0.04% of annual consolidated turnover

Voting Schedule and Process

The company has established a comprehensive e-voting timeline for shareholder participation. Members whose names appear on the Register of Members as of 20th February, 2026 (Cut-Off Date) are eligible to participate in the voting process.

Voting Timeline: Schedule
Voting Commencement: Monday, 2nd March, 2026 at 09:00 a.m. (IST)
Voting Conclusion: Tuesday, 31st March, 2026 at 05:00 p.m. (IST)
Results Announcement: On or before Thursday, 2nd April, 2026
Scrutinizer: M/s. Samdani Shah & Kabra
E-voting Platform: National Securities Depository Limited (NSDL)

Regulatory Compliance and Governance

The postal ballot notice complies with Section 110 read with Section 108 of the Companies Act, 2013, and various SEBI regulations. The professional engagement with Mr. Baheti constitutes a related party transaction under Section 188(1)(f) of the Companies Act, requiring special resolution approval as the fees exceed prescribed monetary limits.

The Audit Committee has reviewed and approved the proposed professional engagement in accordance with the company's Policy on Related Party Transactions. The transaction does not constitute a material related party transaction under SEBI Listing Regulations.

Director Profile and Remuneration

Mr. Rajkumar Baheti, aged 66 years, has drawn remuneration of Rs. 5.35 crores during the financial year 2025-26 up to the notice date. He has attended four Board meetings during the current financial year and holds no shares in the company. Upon appointment as Non-Executive Director, he will be liable to retire by rotation and will continue serving on the Stakeholder Relationship Committee, Risk Management Committee, and Administrative Sub-Committee.

Historical Stock Returns for Alembic Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
-0.99%-9.24%-10.71%-26.02%-6.21%-25.34%
Alembic Pharmaceuticals
View Company Insights
View All News
like15
dislike

More News on Alembic Pharmaceuticals

1 Year Returns:-6.21%